MedTrace Logo

Study to Evaluate the Efficacy and Safety of Lenalidomide in the Treatment of Complex Regional Pain Syndrome Type 1

NCT00109772 · Status: TERMINATED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 184

Last updated 2013-08-28

Study results available
· View outcomes & findings →

Summary

The purpose of this multicenter, double-blind, placebo-controlled study is to evaluate the efficacy and safety of Lenalidomide in adult subjects with Complex Regional Pain Syndrome (CRPS) Type 1.

Conditions

  • Complex Regional Pain Syndrome, Type I

Interventions

DRUG

lenalidomide

Two 5 mg capsules taken one time per day

DRUG

Placebo

Two placebo capsules taken one time per day

Sponsors & Collaborators

  • Celgene Corporation

    lead INDUSTRY

Principal Investigators

  • Donald C Manning, MD, PhD · Celgene Corporation

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2005-02-28
Primary Completion
2008-04-30
Completion
2008-04-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00109772 on ClinicalTrials.gov